
-
Eight OPEC+ alliance members move toward output hike at meeting
-
Prayers for the Dalai Lama in the heart of Mongolian Buddhism
-
Rivals ready to rock as fans flood in for Tour de France opener
-
Djokovic banks on 'home' advantage against Davis Cup teammate at Wimbledon
-
Ozzy Osbourne set for swansong at Black Sabbath hometown gig
-
Family and football unite to bid Diogo Jota farewell
-
Bombers and a 'beautiful bill' -- Trump celebrates US Independence Day
-
Mbappe 'better' and ready for Real Madrid against Dortmund at Club World Cup
-
BRICS nations to denounce Trump tariffs
-
Ghim maintains one-shot lead at PGA's John Deere Classic
-
Bayern Club World Cup clash with PSG a 'perfect storm': Kompany
-
Al Hilal showed Saudi league not just about money, says Koulibaly
-
PSG 'dead' unless they keep improving: Luis Enrique
-
MLB Cubs smash team-record eight homers to crush Cardinals
-
Mark Snow, composer of 'X Files' theme, dead at 78
-
Trump signs 'big, beautiful' bill on US Independence Day
-
US sprinter Richardson seeks to kickstart season after February injury
-
West Indies and Australia 2nd Test finely poised
-
Bosnia ends warrant for Bosnian Serb leader after questioning
-
Germany see off Poland in Women's Euro 2025 opener
-
Alcaraz into Wimbledon last 16 as Sabalenka outlasts Raducanu
-
Fluminense beat Al Hilal 2-1 to reach Club World Cup semis
-
At least 13 dead, 20 missing in Texas flash flood
-
Sabalenka outguns Raducanu to reach Wimbledon last 16
-
BRICS nations to gather without Xi, Putin
-
Heavy snow hits Turkey's northeast as wildfires rage
-
Brazil's Gabigol wins appeal in anti-doping case
-
Salah 'frightened' to return to Liverpool as fans mourn tragic Jota
-
Siraj 'loving the challenge' of leading India's attack against England
-
France says 'major issues' remain despite brandy price accord with China
-
'Always hiding': Haitian laborers fear Dominican deportation push
-
Rugby World Cup-winning Springboks coach White leaves Bulls
-
UK rock legends Oasis kick off 'historic' comeback tour
-
Alcaraz in Wimbledon last 16 as seeds tumble again
-
Kipyegon, Duplantis, Thompson highlight Eugene Diamond League
-
Australia wrest back control against West Indies
-
Erratic Alcaraz battles into Wimbledon fourth round
-
Search on for survivors of Pakistan building collapse
-
Blink and you'll miss it: Shelton wraps up match in 71 seconds
-
India on top despite Smith and Brook's hundred heroics in 2nd Test
-
Sweden beat rivals Norway at Women's Euro 2025
-
India on top despite Smith and Brook's hundred heroics in third Test
-
E.Guinea launches ICJ case against France over Paris mansion
-
Red Bull boss says Verstappen wants to stay despite Mercedes links
-
Russia brushes off talks after largest assault on Ukraine
-
Oldest surviving Tour de France yellow jersey wearer Marinelli dies at 99
-
Driven Leclerc determined to restore Ferrari to the top of F1
-
Dozens pay tribute to Liverpool star Diogo Jota in Portugal
-
Greece on high alert as heat and wind fuel fire outbreaks
-
Norris tops Silverstone practice as Horner quizzed over Verstappen

Avant Technologies and Partner, Ainnova, Receive FDA Pre-Submission Meeting Date for Company’s Vision AI Platform Technology
LAS VEGAS, NEVADA / ACCESS Newswire / May 6, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that the U.S. Food and Drug Administration (FDA) has scheduled its pre-submission meeting with Ainnova's executives and its CRO, Fortrea, for July 7, 2025, to discuss a range of items related to the Company's planned clinical trial of its Vision AI platform in the early detection of diabetic retinopathy.
Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, said, "We are forever grateful for the opportunity to meet with the U.S. FDA to discuss our planned clinical trial. These meetings will give us the direction that we'll need for success and to support our FDA 510(k) submission to obtain clearance from the FDA to market our technology in the U.S."
"We will use this pre-submission meeting to determine a host of items, including the ideal number of clinical sites, the number of total patients needed, and to learn if the FDA will approve our protocol for the planned clinical trial. These are all crucial for both Avant and Ainnova in determining the exact costs and a timetable."
AAC has the worldwide licensing rights for Ainnova's technology portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova's interactions with the FDA are paramount to marketing the technology portfolio in the United States. Entering the U.S. market will unlock significant commercial potential, and this early engagement with the FDA ensures AAC can do so with speed, credibility, and a validated product.
About Ainnova Tech, Inc.
Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI - our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
About Avant Technologies Inc.
Avant Technologies Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies Inc.
[email protected]
SOURCE: Avant Technologies
View the original press release on ACCESS Newswire
L.Harper--AMWN